{"id":34579,"date":"2025-06-10T12:36:17","date_gmt":"2025-06-10T16:36:17","guid":{"rendered":"https:\/\/advisory.avalerehealth.com\/?p=34579"},"modified":"2025-06-10T12:36:17","modified_gmt":"2025-06-10T16:36:17","slug":"stakeholder-considerations-for-ipay-2028-guidance","status":"publish","type":"post","link":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance","title":{"rendered":"Stakeholder Considerations for IPAY 2028 Guidance"},"content":{"rendered":"<p><span data-contrast=\"auto\">On May 12, the Centers for Medicare &amp; Medicaid Services (CMS) released <\/span><a href=\"https:\/\/www.cms.gov\/files\/document\/ipay-2028-draft-guidance.pdf\"><span data-contrast=\"none\">draft guidance<\/span><\/a><span data-contrast=\"auto\"> detailing the selection and negotiation processes for Medicare Part B and Part D drugs for Initial Price Applicability Year (IPAY) 2028. This guidance builds upon the framework established in previous years and introduces several key changes, including the eligibility of Part B drugs for selection.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><b><span data-contrast=\"auto\">Key Changes for IPAY 2028<\/span><\/b><\/p>\n<ul>\n<li><b><span data-contrast=\"auto\">Drug Selection and Eligibility<\/span><\/b><span data-contrast=\"auto\">:<\/span><span data-ccp-props=\"{}\">\u00a0<\/span>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"6\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Part B Drug Inclusion:<\/span><\/b><span data-contrast=\"auto\"> For the first time, Part B drugs will be eligible for selection. CMS will identify the top-50 Part B and Part D drugs separately before aggregating the lists and spending to identify the 15 drugs for IPAY 2028 negotiation.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"6\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Small Biotech Exclusion (SBE):<\/span><\/b><span data-contrast=\"auto\"> Manufacturers can apply for SBE under Part B and\/or Part D tracks, with an exception granted if either track is met. The SBE application is drug-specific and, if granted, will make a drug ineligible for selection in IPAY 2028, the last year for SBE applications.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"6\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Combination Drugs:<\/span><\/b><span data-contrast=\"auto\"> CMS is seeking comments on how to treat drugs with additional active ingredients that affect bioavailability but are not biologically active against the disease.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"6\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Changes to the Negotiation Process<\/span><\/b><span data-contrast=\"auto\">:<\/span><span data-ccp-props=\"{}\">\u00a0<\/span>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Ceiling Calculation:<\/span><\/b><span data-contrast=\"auto\"> CMS proposed a methodology to incorporate Part B prices and utilization into ceiling calculations and estimate the 30-day equivalent supply for Part B drugs that differs from the current Part D methodology.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Single Maximum Fair Price (MFP) across Part B and Part D:<\/span><\/b><span data-contrast=\"auto\"> For drugs covered under Part B and Part D, CMS clarified that it will calculate a single MFP to use across formulations and benefit type.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Therapeutic Alternative (TA) Considerations:<\/span><\/b><span data-contrast=\"auto\"> CMS is seeking comments on proposed alternative methods for consideration of TAs when developing the initial offer starting point, including the evidence it will consider. In addition, CMS is seeking comment on whether and how to consider non-drug healthcare services when evaluating TAs.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Data Collection:<\/span><\/b><span data-contrast=\"auto\"> CMS seeks comment on the collection of additional market data that is \u201cforward-looking\u201d and overlaps with the period between selection and start of the IPAY. CMS provided two examples of the type of data that might be included and noted that these data are consistent with section 1194(e)(1)(E) language of \u201cmarket data and revenue and sales volume data for the drug in the United States.\u201d<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Part B MFP Effectuation:<\/span><\/b><span data-contrast=\"auto\"> CMS did not propose a standard default refund amount approach for <\/span><a href=\"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-mfp-effectuation-in-part-b\"><span data-contrast=\"none\">Part B effectuation<\/span><\/a><span data-contrast=\"auto\">, leaving room for stakeholder input. However, CMS did note that it intends to align the process as closely as possible to Part D processes. Additionally, CMS did not describe the role of the Medicare Transaction Facilitator in Part B, but noted that Part B has different supply chain considerations that its effectuation processes.<\/span><span data-ccp-props=\"{&quot;335559685&quot;:360}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Part D Formulary Management<\/span><\/b><span data-contrast=\"auto\">: CMS clarified that Part D sponsors may remove a selected drug if substituted with a generic or interchangeable biological product, subject to specific requirements.<\/span><span data-ccp-props=\"{&quot;335559685&quot;:360}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"1\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;multilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Renegotiation Criteria: <\/span><\/b><span data-contrast=\"auto\">CMS clarified conditions for drug renegotiation, including changes in monopoly status or significant market changes that may result in a greater than 15% change in MFP.<\/span><\/li>\n<\/ul>\n<p><b style=\"color: var(--wpex-text-2); font-family: var(--wpex-body-font-family, var(--wpex-font-sans)); font-size: var(--wpex-body-font-size, var(--wpex-text-base, 1rem));\"><span data-contrast=\"auto\">Implications for Stakeholders<\/span><\/b><span style=\"color: var(--wpex-text-2); font-family: var(--wpex-body-font-family, var(--wpex-font-sans)); font-size: var(--wpex-body-font-size, var(--wpex-text-base, 1rem));\" data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Stakeholders have an important opportunity to engage CMS during this process to provide insight into the operationalization of guidance policies and access implications. Below are several stakeholder-specific business questions that are likely to shape response and comment strategy.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<ul>\n<li><b><span data-contrast=\"auto\">Manufacturers<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">How will potential changes to the CMS definition of a combination product directly and indirectly impact the expected negotiation selection timing? What are the possible implications for the competitive market, pipeline planning, and forecasting?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">To what extent may CMS\u2019s proposed 30-day price for Part B alternatives lower the expected starting point for selected drugs with Part B therapeutic alternatives?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">How can manufacturers shape the MFP effectuation process in Part B to minimize access disruptions?\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">How could the Part B standard default refund amount (SDRA) impact manufacturer gross to net provider economics, and supply chain dynamics? Should manufacturers adjust volume-based rebates to account for Medicare beneficiaries eligible for MFP?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Payers<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\"><span data-contrast=\"auto\">To what extent may updated formulary management guidance shift management of negotiated products?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\"><span data-contrast=\"auto\">How does introducing MFPs into the market impact non-Medicare plans based on current or future contract language, relative to the reimbursement mechanism?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\"><span data-contrast=\"auto\">To what extent may plans align their preferred drugs across books of business (e.g., Medicare, commercial, etc.)?\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"5\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Dispensing Entities and Part B Providers<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"8\" data-aria-level=\"1\"><span data-contrast=\"auto\">How will Part D effectuation impact the ability to stock and dispense negotiated drugs, given the lag in MFP-based reimbursement and the SDRA true-up?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"8\" data-aria-level=\"1\"><span data-contrast=\"auto\">How will Part B effectuation impact Part B provider economics? How might this impact the ability to carry and supply negotiated products?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"8\" data-aria-level=\"1\"><span data-contrast=\"auto\">Is there a preferred alternative SDRA method that mitigates the risk to provider economics?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"8\" data-aria-level=\"1\"><span data-contrast=\"auto\">How might Group Purchasing Organization and distributor contracts change after part B effectuation?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"4\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"8\" data-aria-level=\"1\"><b><span data-contrast=\"auto\">Patients<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span>\n<ul>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"5\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">How will the Inflation Reduction Act (IRA) impact shared decision making and access to treatments? Will this change prompt patients to change drugs and\/or how they receive them?\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"5\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">What is the impact of MFP on out-of-pocket (OOP) cost? Is there a meaningful difference between the Part D OOP cap and the Medicare Prescription Payment Plan? How much will OOP cost change for negotiated drugs if patients use supplemental insurance to help pay for Part B drugs?\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<li data-leveltext=\"\uf0b7\" data-font=\"Symbol\" data-listid=\"5\" data-list-defn-props=\"{&quot;335552541&quot;:1,&quot;335559685&quot;:720,&quot;335559991&quot;:360,&quot;469769226&quot;:&quot;Symbol&quot;,&quot;469769242&quot;:[8226],&quot;469777803&quot;:&quot;left&quot;,&quot;469777804&quot;:&quot;\uf0b7&quot;,&quot;469777815&quot;:&quot;hybridMultilevel&quot;}\" aria-setsize=\"-1\" data-aria-posinset=\"1\" data-aria-level=\"1\"><span data-contrast=\"auto\">What patient advocacy organizations are involved in IRA negotiation discussions? How can patients join these groups and participate in patient roundtable opportunities?<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><b><span data-contrast=\"auto\">Next Steps<\/span><\/b><span data-ccp-props=\"{}\">\u00a0<\/span><br \/>\n<span data-contrast=\"auto\">CMS invites public comment through June 26, 2025, to inform the final guidance. Several proposed changes, including the collection of forward-looking financial information and potential changes to factor weighting, indicate potential for additional downward pressure on MFPs. Manufacturer stakeholders should analyze the potential impact of these changes on their portfolios and consider submitting comments to shape policy and mitigate risks. Provider and patient stakeholders should consider how the unintended consequences of the IRA may impact access to care and their ability to continue to treat patients.\u00a0<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Previous Avalere Health analyses have assessed the impact of MFP on\u202f<\/span><a href=\"https:\/\/advisory.avalerehealth.com\/insights\/commercial-spillover-impact-of-part-b-negotiations-on-physicians\"><span data-contrast=\"none\">provider reimbursement<\/span><\/a><span data-contrast=\"auto\">\u202fand\u202f<\/span><a href=\"https:\/\/advisory.avalerehealth.com\/insights\/estimating-the-spillover-impact-of-ira-part-b-negotiation\"><span data-contrast=\"none\">potential spillover effects<\/span><\/a><span data-contrast=\"auto\">\u202fthat can shed light on some unintended consequences of Part B negotiations. <\/span><a href=\"https:\/\/pages.avalere.com\/Keep-In-Touch.html?_gl=1*1jw28dd*_gcl_au*OTQ1NDgzMjkzLjE3NDUyNzk4NzA.*_ga*MTM4MjYyODI3Ny4xNzI5NTE2MzAx*_ga_1LKSE3H6ZT*MTc0NTg1NjY0MC4yNDguMS4xNzQ1ODU3MjI1LjYwLjAuMA..\"><span data-contrast=\"none\">Connect with us<\/span><\/a><span data-contrast=\"auto\">\u202fto learn more about how Avalere Health supports client\u2019s policy, access, pricing, contracting and channel strategy related to Part B negotiations.<\/span><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{}\">\u00a0<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On May 12, the Centers for Medicare &amp; Medicaid Services (CMS) released draft guidance detailing the selection and negotiation processes for Medicare Part B and Part D drugs for Initial Price Applicability Year (IPAY) 2028. This guidance builds upon the framework established in previous years and introduces several key changes, including the eligibility of Part&hellip;<\/p>\n","protected":false},"author":28,"featured_media":23463,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[1001],"content-categories":[259],"class_list":["post-34579","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights","tag-ira","content-categories-policy","entry","has-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Stakeholder Considerations for IPAY 2028 Guidance | Avalere Health Advisory<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stakeholder Considerations for IPAY 2028 Guidance | Avalere Health Advisory\" \/>\n<meta property=\"og:description\" content=\"On May 12, the Centers for Medicare &amp; Medicaid Services (CMS) released draft guidance detailing the selection and negotiation processes for Medicare Part B and Part D drugs for Initial Price Applicability Year (IPAY) 2028. This guidance builds upon the framework established in previous years and introduces several key changes, including the eligibility of Part&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance\" \/>\n<meta property=\"og:site_name\" content=\"Avalere Health Advisory\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-10T16:36:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/09\/23462-1-Brooke_Fruman-400x600-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Leah Keller\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@avalerehealth\" \/>\n<meta name=\"twitter:site\" content=\"@avalerehealth\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Leah Keller\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stakeholder Considerations for IPAY 2028 Guidance | Avalere Health Advisory","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance","og_locale":"en_US","og_type":"article","og_title":"Stakeholder Considerations for IPAY 2028 Guidance | Avalere Health Advisory","og_description":"On May 12, the Centers for Medicare &amp; Medicaid Services (CMS) released draft guidance detailing the selection and negotiation processes for Medicare Part B and Part D drugs for Initial Price Applicability Year (IPAY) 2028. This guidance builds upon the framework established in previous years and introduces several key changes, including the eligibility of Part&hellip;","og_url":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance","og_site_name":"Avalere Health Advisory","article_published_time":"2025-06-10T16:36:17+00:00","og_image":[{"width":600,"height":400,"url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/09\/23462-1-Brooke_Fruman-400x600-1.jpg","type":"image\/jpeg"}],"author":"Leah Keller","twitter_card":"summary_large_image","twitter_creator":"@avalerehealth","twitter_site":"@avalerehealth","twitter_misc":{"Written by":"Leah Keller","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance#article","isPartOf":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance"},"author":{"name":"Leah Keller","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/fb195190cdd6a0c7c2cc890515dd95f4"},"headline":"Stakeholder Considerations for IPAY 2028 Guidance","datePublished":"2025-06-10T16:36:17+00:00","dateModified":"2025-06-10T16:36:17+00:00","mainEntityOfPage":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance"},"wordCount":1026,"commentCount":0,"publisher":{"@id":"https:\/\/advisory.avalerehealth.com\/#organization"},"image":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance#primaryimage"},"thumbnailUrl":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/09\/23462-1-Brooke_Fruman-400x600-1.jpg","keywords":["ira"],"articleSection":["Insights &amp; Analysis"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance#respond"]}]},{"@type":"WebPage","@id":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance","url":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance","name":"Stakeholder Considerations for IPAY 2028 Guidance | Avalere Health Advisory","isPartOf":{"@id":"https:\/\/advisory.avalerehealth.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance#primaryimage"},"image":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance#primaryimage"},"thumbnailUrl":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/09\/23462-1-Brooke_Fruman-400x600-1.jpg","datePublished":"2025-06-10T16:36:17+00:00","dateModified":"2025-06-10T16:36:17+00:00","breadcrumb":{"@id":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance#primaryimage","url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/09\/23462-1-Brooke_Fruman-400x600-1.jpg","contentUrl":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2021\/09\/23462-1-Brooke_Fruman-400x600-1.jpg","width":600,"height":400,"caption":"Brooke Fruman"},{"@type":"BreadcrumbList","@id":"https:\/\/advisory.avalerehealth.com\/insights\/stakeholder-considerations-for-ipay-2028-guidance#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/advisory.avalerehealth.com\/"},{"@type":"ListItem","position":2,"name":"Stakeholder Considerations for IPAY 2028 Guidance"}]},{"@type":"WebSite","@id":"https:\/\/advisory.avalerehealth.com\/#website","url":"https:\/\/advisory.avalerehealth.com\/","name":"Avalere Health Advisory","description":"","publisher":{"@id":"https:\/\/advisory.avalerehealth.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/advisory.avalerehealth.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/advisory.avalerehealth.com\/#organization","name":"Avalere Health","url":"https:\/\/advisory.avalerehealth.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/logo\/image\/","url":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2025\/03\/avalere-health-logo-cropped-white_1x.webp","contentUrl":"https:\/\/advisory.avalerehealth.com\/wp-content\/uploads\/2025\/03\/avalere-health-logo-cropped-white_1x.webp","width":433,"height":47,"caption":"Avalere Health"},"image":{"@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/avalerehealth"]},{"@type":"Person","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/fb195190cdd6a0c7c2cc890515dd95f4","name":"Leah Keller","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/advisory.avalerehealth.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4a87f9cf63da84fab5720429686278df?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4a87f9cf63da84fab5720429686278df?s=96&d=mm&r=g","caption":"Leah Keller"},"description":"Leah Keller co-manages and edits the Policy 360 Research Series sits on Avalere\u2019s Marketing Team. Prior to joining Avalere, Leah conducted policy research and analysis on federal healthcare issues such as Medicaid coverage and payment, commercial insurance coverage and access, healthcare reform, and ACA implementation at the Guttmacher Institute, a thinktank focused on advancing reproductive health and rights. Prior, Leah coordinated data collection, analysis, and publications for George Washington University\u2019s Center for Social Well-Being and Development. Leah holds an MPH in maternal and child health from George Washington University and a BA in anthropology from St. Mary\u2019s College of Maryland.","url":"https:\/\/advisory.avalerehealth.com\/author\/lkelleravalere-com"}]}},"_links":{"self":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/34579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/comments?post=34579"}],"version-history":[{"count":8,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/34579\/revisions"}],"predecessor-version":[{"id":34587,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/posts\/34579\/revisions\/34587"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/media\/23463"}],"wp:attachment":[{"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/media?parent=34579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/categories?post=34579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/tags?post=34579"},{"taxonomy":"content-categories","embeddable":true,"href":"https:\/\/advisory.avalerehealth.com\/wp-json\/wp\/v2\/content-categories?post=34579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}